Brigatinib AAF

Small molecule

Brigatinib AAF is one of 4 small molecule programs targeting Inflammatory Myofibroblastic Tumor. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Myofibroblastic TumorActive, not recruiting

Inflammatory Myofibroblastic TumorPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Inflammatory Myofibroblastic Tumor

#DrugCompanyPhaseTrials

Zykadia

Novartis

Approved

—2

Xalkori

PPrism Pharmaceuticals

Alunbrig

1 4

Brigatinib AAF

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Inflammatory Myofibroblastic Tumor1 trial

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Withdrawn· Takeda logo

Takeda·Phase 1/2·NCT04260009

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Brigatinib AAF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brigatinib AAF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brigatinib AAF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Takeda

Brigatinib AAF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Inflammatory Myofibroblastic Tumor1 trial

References

Drug Info

Quick Facts

Related News